Table 3 Univariate and multivariate analysis of the prognostic value of miR-25 and miR-142 in OS
Variables | Number of patients | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
HR (95%CI) | P value | HR (95%CI) | P value | ||
Age | 380 | 1.036 (1.014–1.058) | 0.001 | 1.033 (1.010–1.056) | 0.004 |
Stage | Â | Â | 0.003 | Â | 0.012 |
 Early | 51 | 1 |  | 1 |  |
 Late | 329 | 5.661 (1.792–17.885) | 4.229 (1.324–13.515) | ||
Grade | Â | Â | 0.798 | Â | / |
 Low | 74 | 1 |  | / |  |
 High | 281 | 1.069 (0.644–1.774) |  | / |  |
 NA | 25 | / |  | / |  |
Debulking | Â | Â | 0.002 | Â | 0.074 |
 Optimal | 290 | 1 |  | 1 |  |
 Suboptimal | 88 | 1.991 (1.299–3.050) |  | 1.497 (0.962–2.328) |  |
 Inoperable | 2 | / |  |  |  |
Treatment | Â | Â | 0.072 | Â | 0.087 |
 Standard | 181 | 1 |  | 1 |  |
 Standard+Bevacizumab | 199 | 0.692 (0.463–1.034) |  | 0.702 (0.468–1.052) |  |
miR-25 expression | Â | Â | 0.009 | Â | 0.013 |
 Low | 341 | 1 |  | 1 |  |
 High | 39 | 0.217 (0.069–0.687) |  | 0.233 (0.073–0.738) |  |
miR-142 expression | Â | Â | 0.052 | Â | 0.091 |
 Low | 99 | 1 |  | 1 |  |
 High | 281 | 1.648 (0.996–2.727) |  | 1.547 (0.933–2.566) |  |